Emcure Pharmaceuticals has announced a major 55% price reduction for the starting dose of its weight-management drug, Poviztra® (semaglutide injection). Effective April 3, 2026, the starting monthly cost will be ₹3,999. This strategic move aims to make scientifically validated obesity treatments more affordable and accessible, addressing India’s growing obesity epidemic which impacts millions of individuals suffering from related health complications.
Strategic Price Revision
Emcure Pharmaceuticals has officially announced a significant downward revision in the pricing of Poviztra®, its semaglutide injection used for weight management. By cutting the starting dose price by 55%, the company intends to enhance accessibility for a broader patient base across India. Across all available dosage strengths, prices have been reduced by an average of 47%, effective from April 3, 2026.
New Monthly Pricing Structure
The revised monthly costs for the once-weekly pen device are as follows:
- Poviztra® 0.25 mg: ₹3,999/-
- Poviztra® 0.5 mg: ₹4,999/-
- Poviztra® 1 mg: ₹5,999/-
- Poviztra® 1.7 mg: ₹7,999/-
- Poviztra® 2.4 mg: ₹8,999/-
Addressing the Obesity Epidemic
With an estimated 254 million people in India living with generalized obesity and 351 million affected by abdominal obesity, the need for affordable therapeutic interventions is critical. Satish Mehta, CEO and Managing Director of Emcure Pharma, emphasized that this price reduction is a vital step in supporting patients struggling with weight-related health challenges, which are linked to over 230 complications, including type 2 diabetes and cardiovascular disease.
Proven Therapeutic Solution
Poviztra® utilizes the innovator semaglutide molecule, which is supported by nearly 50 clinical trials and has a decade of real-world global use, representing 49+ million patient years of exposure. Emcure Pharma remains the first Indian company to exclusively distribute and commercialize this advanced therapy, reinforcing its commitment to improving health outcomes through accessible innovation.
Source: BSE
